News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rosetta Genomics Ltd. (ROSG) to Receive Important U.S. Patent for Oncology Therapeutic



2/26/2014 12:08:50 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PRINCETON, NJ and REHOVOT, ISRAEL--(Marketwired - Feb 26, 2014) - Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent claiming Mp53-negative cancer patients. The allowed claims for U.S. Patent Application No. 12/528,690 entitled "Composition and Methods for Modulating Cell Proliferation and Cell Death," cover a core element of Rosetta Genomics' microRNA technology in the development of cancer therapeutics associated with non-small cell lung cancer (NSCLC) in p53-negative patients. The allowed patent application is jointly owned with Yeda, the technology transfer company of the Weizmann Institute of Science in Rehovot, Israel.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES